Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Receivables (2023 - 2024)

Capricor Therapeutics (CAPR) has 3 years of Receivables data on record, last reported at $20.4 million in Q4 2024.

  • For Q4 2024, Receivables changed 0.02% year-over-year to $20.4 million; the TTM value through Dec 2024 reached $20.4 million, changed 0.02%, while the annual FY2024 figure was $20.4 million, 0.02% changed from the prior year.
  • Receivables reached $20.4 million in Q4 2024 per CAPR's latest filing, roughly flat from $20.4 million in the prior quarter.
  • Across five years, Receivables topped out at $20.4 million in Q4 2023 and bottomed at $20.4 million in Q4 2024.